Ocular Lyme Disease Rarely Presents the Same Way Twice
Ocular involvement in Lyme disease remains uncommon, but when it appears it can reach nearly every layer of the eye and the visual pathway. A retrospective case series spanning published reports from 1988 through 2025 pulled together 38 cases of ocular Lyme disease and found a strikingly varied clinical picture: uveitis led the list, followed by optic neuritis and cranial nerve palsies. The pattern matters because eye findings may be the first clue to a disseminated infection, yet they are easy to misclassify as autoimmune disease, idiopathic inflammation, or another tick-borne syndrome.
The most common manifestation across the reviewed cases was uveitis, present in 17 patients. Cranial neuropathies were another recurring theme, especially sixth nerve palsy, which can immediately disrupt ocular alignment and produce diplopia. Optic neuritis, papillitis, retinal vasculitis, optic disc edema, scleritis, interstitial keratitis, ocular flutter, opsoclonus, and internuclear ophthalmoplegia all appeared in the case literature as well. The clinical lesson is not that Lyme disease causes one characteristic eye syndrome; it is that ocular Lyme disease can mimic several different inflammatory and neurologic disorders at once.
Microbiologic Proof Was Uncommon but Clinically Important
Only 5 of the 38 cases had microbiologic proof of infection. Those confirmed cases included 2 anterior uveitis cases, 1 intermediate uveitis case, 1 case of anterior uveitis with abducens nerve palsy, and 1 case of intranuclear ophthalmoplegia. In practical terms, that small number is a reminder that many published ocular Lyme cases rest on a presumptive diagnosis, often because the report predates current surveillance definitions or because the workup did not capture direct evidence of infection.
Microbiologic confirmation came from multiple sources: corneal tissue, vitreous fluid, aqueous humor, and cerebrospinal fluid. One man with progressive crystalline keratopathy had spirochete-like organisms seen on microscopy and positive broad-range 16S rDNA PCR testing for Borrelia burgdorferi sensu lato. Another patient with pars planitis had vitreous fluid PCR-positive for B. burgdorferi. A woman with systemic symptoms and subsequent iritis, hypopyon, and vitritis had intact spirochetes identified in a surgical specimen, while serologic testing for Treponema pallidum remained negative. In a separate case, aqueous humor contained Borrelia DNA in a patient with abducens nerve palsy and anterior uveitis. A man with bilateral internuclear ophthalmoplegia had cerebrospinal fluid PCR positive for Borrelia spp., and repeat lumbar puncture 3 months later was negative after treatment.
Those cases show why microbiologic proof remains valuable even in a disease that is often diagnosed clinically. Direct detection links the ocular syndrome to the infection itself, strengthens epidemiologic interpretation, and reduces the risk of treating the wrong inflammatory process.
One diagnosis without proof can send a patient down the wrong therapeutic path.
The Eye Findings Often Followed Systemic Lyme Clues
The case series also shows that ocular disease rarely arrived in isolation. Systemic symptoms such as fatigue, arthralgia, and influenza-like illness appeared frequently, and several patients had a history of recent tick bite or erythema migrans. In one microbiologically confirmed case, a 45-year-old woman developed fever, chills, headache, light-headedness, and an erythema migrans–like rash before iritis and then a more aggressive inflammatory course. Another patient with confirmed abducens palsy and anterior uveitis had recent tick exposure, erythema migrans, arthralgia, and diplopia. These combinations matter because Lyme disease is a multisystem infection; ocular inflammation may be one manifestation of a broader disseminated process rather than a stand-alone eye disorder.
The biology fits that pattern. After inoculation by an Ixodes tick, B. burgdorferi can spread beyond the skin and trigger neurologic, cardiac, musculoskeletal, and ocular manifestations over weeks to months. The eye sits at the intersection of immune privilege and vascular access, which may help explain why inflammatory syndromes such as uveitis or optic neuritis emerge in some patients while cranial neuropathies dominate in others. The case series does not prove a single pathophysiologic pathway for every ocular presentation, but it does reinforce the idea that the same infection can travel through distinct anatomic routes and produce very different bedside findings.
Treatment Responses Varied, and Steroids Alone Could Be Misleading
The treatment stories in the case series are as clinically revealing as the diagnoses. Several patients improved after antimicrobial therapy, including intravenous ceftriaxone or oral doxycycline, sometimes alongside topical or systemic anti-inflammatory therapy. The patient with bilateral internuclear ophthalmoplegia recovered after 3 weeks of intravenous ceftriaxone. The woman with anterior uveitis and abducens nerve palsy improved after topical steroids plus 2 weeks of ceftriaxone. Another patient with unilateral intermediate uveitis initially received oral doxycycline, later intravenous ceftriaxone, and had a complicated course that included severe thrombocytopenia and eventual vitrectomy.
A different case illustrates the hazard of treating inflammatory eye disease without firm etiologic clarity. A woman with systemic symptoms, iritis, and later severe panophthalmitis received subconjunctival triamcinolone and then oral prednisone up to 100 mg/day, yet the inflammation worsened and progressed to orbital cellulitis requiring multiple procedures. Her specimen later showed spirochetes. While the series cannot establish causation from a single case, it does show how rapidly ocular Lyme disease can be misread as a purely inflammatory condition and how steroid-heavy treatment may fail to halt infection-driven pathology if antibiotics are delayed or absent.
The corneal case was equally sobering. Despite intravenous ceftriaxone and continued immunosuppression, the crystalline keratopathy remained unchanged over prolonged follow-up. Persistent structural damage may linger even after the infection is treated, especially when the eye has already undergone surgery or when chronic inflammation has altered tissue architecture.
Why This Case Series Changes the Diagnostic Threshold
The review screened 176 articles and found 27 publications that met criteria for analysis, with 2 additional texts excluded because no English version was available. The scarcity of eligible reports does not weaken the message; it defines the challenge. Ocular Lyme disease is rare in the literature, variably documented, and often diagnosed without the benefit of direct microbiologic confirmation. Yet the range of presentations is broad enough that clinicians need a low threshold to consider Lyme disease when eye inflammation, cranial nerve palsy, optic neuritis, or unexplained diplopia appears in the right epidemiologic setting.
Surveillance criteria should not be mistaken for bedside rules. The case series makes that distinction explicit by noting that some older reports did not meet current CDC definitions, which are intended for surveillance rather than individual diagnosis. For clinicians, the more useful standard is to pair ocular findings with exposure history, systemic symptoms, and laboratory support whenever possible. Where ocular fluid, tissue, or cerebrospinal fluid can be sampled safely, microbiologic confirmation adds diagnostic weight and can settle uncertainty when the presentation overlaps with syphilis, autoimmune uveitis, demyelinating disease, or other infectious mimics.
The takeaway is narrow but concrete: ocular Lyme disease can present as uveitis, optic nerve inflammation, cranial neuropathy, or mixed inflammatory-neurologic disease, and the best-supported cases were those with microbiologic evidence. The remaining uncertainty sits in the many presumptive reports, where the clinical picture is suggestive but not definitive, and where future case capture will need better specimen-based confirmation to define how often the eye is truly involved.